Back to Search
Start Over
Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics.
- Source :
- ERJ Open Research; Jan2024, Vol. 10 Issue 1, p1-12, 12p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 23120541
- Volume :
- 10
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- ERJ Open Research
- Publication Type :
- Academic Journal
- Accession number :
- 175973174
- Full Text :
- https://doi.org/10.1183/23120541.00509-2023